Revenue Outperformance and the Initial Biosimilar Inroad
Roche's third-quarter commercial disclosures highlighted stark operational divergence across its portfolio, as group revenue expanded to 16.13 billion Swiss francs, outpacing consensus forecasts primarily through robust demand for its multiple sclerosis franchise Ocrevus, which climbed 9% to 1.84 billion francs. Simultaneously, the specialized diagnostics division advanced 5% to 3.54 billion francs, with operational drag stemming from centralized healthcare procurement reforms in mainland China beginning to moderate substantially.
Nevertheless, commercial achievements were clouded by competitive setbacks confronting blockbusters nearing exclusivity loss.

















